<DOC>
	<DOCNO>NCT00003101</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy autologous bone marrow transplantation peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus bone marrow transplantation peripheral stem cell transplantation treat patient oligodendroglioma .</brief_summary>
	<brief_title>Combination Chemotherapy Bone Marrow Transplantation Peripheral Stem Cell Transplantation Treating Patients With Oligodendroglioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine duration response patient newly diagnose pure mixed anaplastic oligodendrogliomas treat intensive chemotherapy support autologous transplantation . - Determine neurological systemic toxic effect regimen patient . - Determine relationship 1p loss heterozygosity radiographic response , progression-free survival , overall survival patient treat regimen . OUTLINE : This multicenter study . - Mobilization stem cell harvest : Patients receive filgrastim ( G-CSF ) subcutaneously daily 7 day follow peripheral blood stem cell ( PBSC ) bone marrow ( BM ) harvest . - Induction therapy : All patient receive induction therapy ( PCV ) comprise oral lomustine day 1 , vincristine IV day 8 29 , oral procarbazine day 8-21 . Treatment repeat every 42 day absence progressive disease unacceptable toxicity . Patients prior complete resection receive 3 course PCV proceed high-dose chemotherapy transplantation describe , provide tumor recur . Patients prior partial resection biopsy receive 2 course PCV assess response ; achieve complete response ( CR ) major partial response ( PR ) receive 1 course PCV . Patients achieve partial response stable disease receive 2 course PCV reassess . - High-dose chemotherapy transplantation : Patients achieve CR PR receive thiotepa IV day -8 -6 busulfan IV 2 hour day -5 -3 . Patients undergo autologous BM PBSC transplantation day 0 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study within 3-5 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven anaplastic oligodendroglioma OR Histologically proven anaplastic mixed glioma ( oligoastrocytoma ) provide unequivocal substantial ( least 25 % ) oligodendroglial element No systemic leptomeningeal metastasis ( exclude contiguous leptomeninges ) PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) OR SGOT great 2 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular LVEF least 50 % Pulmonary DLCO least 50 % predict Other No serious illness would preclude study therapy No concurrent malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior cranial radiotherapy Surgery Prior complete partial resection , open biopsy , stereotactic biopsy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
</DOC>